1. Why Potency Is Difficult in Cell Therapy
Cell therapy products are living, variable, and often multifunctional. A small-molecule potency assay may measure one defined interaction. A cell therapy potency strategy may need to connect phenotype, function, process history, and intended clinical activity into a coherent control strategy.
The trap is choosing an assay because it is convenient. A defensible potency strategy starts with product understanding: what the cell is supposed to do, which attributes plausibly matter, and which test results would change a development or release decision.
2. The Six-Layer Strategy
Early teams do not need a finished commercial potency package on day one. They do need a structured path from exploratory biology to controlled, reviewable assays.
Mechanism-of-action logic
Define the plausible biological function the product is expected to perform. The assay strategy should be connected to that function, not only to easy-to-measure markers.
Critical quality attributes
Identify attributes that may affect safety, identity, purity, viability, consistency, and biological activity. Potency does not live separately from the broader quality picture.
Functional assays
Use functional readouts where possible, such as differentiation, immunomodulation, target-cell interaction, cytokine response, killing activity, or matrix formation depending on the product.
Phenotype and identity support
Surface markers, gene-expression patterns, morphology, and viability may support interpretation, but they need a reasoned link to function.
Process controls
Media, passage number, culture duration, cryopreservation, thaw recovery, and release timing can all affect potency. The manufacturing process should protect the assay signal.
Progressive validation
Early assays may be exploratory. As development advances, methods need qualification, controls, reference materials, acceptance criteria, and change management.
3. Assay-Selection Questions
A useful potency assay should do more than generate a graph. It should support product understanding, process control, and risk-based decisions.
- What biological activity should the product perform in the intended context?
- Which assay result would make the team reject or investigate a batch?
- Is the assay sensitive to meaningful process changes?
- Can the assay distinguish strong, weak, and failed product lots?
- Are reference materials, controls, and sample handling defined?
- Is the assay practical at the point in the process where release decisions are needed?
- What changes would trigger comparability work or regulatory discussion?
4. Common Planning Mistakes
| Mistake | Why it hurts later |
|---|---|
| Treating viability as potency | Viability matters, but it does not usually prove relevant biological activity by itself. |
| Waiting until GMP transfer | Late assay development forces teams to defend weak methods under time pressure. |
| Ignoring process sensitivity | If the assay cannot detect meaningful process changes, it may not protect product consistency. |
| No reference material plan | Without controls or reference materials, method drift and inter-run interpretation become difficult. |
| Changing assays without comparability logic | Assay changes can disrupt historical interpretation unless bridging is planned. |
Potency work should be connected to the broader GMP quality system checklist and your research-to-GMP transition plan.
5. Evidence Sources
This guide draws on FDA potency, biological product specification, pharmaceutical quality, quality-risk-management, and CGMP references.
- FDA: Potency Tests for Cellular and Gene Therapy Products
- FDA: Potency Assurance for Cellular and Gene Therapy Products, Draft Guidance
- FDA/ICH Q6B: Specifications, Test Procedures, and Acceptance Criteria
- FDA/ICH Q9(R1): Quality Risk Management
- FDA/ICH Q10: Pharmaceutical Quality System
- FDA: Current Good Manufacturing Practice (CGMP) Regulations
6. Frequently Asked Questions
What is a potency assay in cell therapy?
A potency assay is a test or set of tests intended to measure biological activity linked to the product and its intended effect. For cell therapies, potency strategy often requires multiple complementary assays rather than one simple measurement.
When should potency assay planning begin?
Planning should begin early in development, before GMP scale-up pressure. Early assays can be imperfect, but teams should start building mechanism-of-action logic, critical quality attributes, reference materials, and comparability thinking as the process matures.
Can one marker prove potency?
Usually not. A single surface marker or viability measure may support identity or quality, but potency should be connected to relevant biological activity. Many cell therapy programs need a matrix of functional, phenotypic, and process-linked evidence.
Need help making potency strategy more defensible?
CellXperience can help connect product biology, assay design, quality risk, and GMP-readiness into a practical development roadmap.